Novo Nordisk On Track For The Worst Day Since 2002 As Its Under-Trial Oral Weight Loss Drug Disappoints, Meets Goldman’s “Disaster” Threshold
In what was being dubbed as the last major big market cap event of the year, Novo Nordisk has finally disclosed the results of the phase 3 trial for its…